January 10, 2018 / 12:12 PM / 5 months ago

BRIEF-Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort

* GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT

* GLAUKOS CORP - COMPANY PREPARES TO COMMENCE PHASE III U.S. IND STUDY IN FIRST HALF OF 2018

* GLAUKOS CORP - COMPANY BEGINS PROCESS FOR IDOSE TRAVOPROST REGULATORY APPROVAL IN EUROPE AND JAPAN

* GLAUKOS CORP - CONDUCTED A PRODUCTIVE END-OF-PHASE II MEETING WITH FDA IN LATE 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below